Pivotal Research upgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a buy rating in a report issued on Wednesday, MarketBeat reports. The firm currently has $135.00 price objective on the stock.
Shares of USANA Health Sciences stock opened at $108.59 on Wednesday. USANA Health Sciences has a 12-month low of $64.20 and a 12-month high of $137.95. The firm has a market cap of $2.63 billion, a P/E ratio of 22.16 and a beta of 0.61.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 23rd. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The firm had revenue of $296.80 million during the quarter, compared to the consensus estimate of $289.54 million. USANA Health Sciences had a return on equity of 30.37% and a net margin of 7.57%. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.03 EPS. On average, analysts forecast that USANA Health Sciences will post 4.9 EPS for the current fiscal year.
In other USANA Health Sciences news, major shareholder Global Ltd Gull acquired 10,396 shares of USANA Health Sciences stock in a transaction on Tuesday, December 11th. The stock was purchased at an average price of $70.70 per share, for a total transaction of $734,997.20. Following the purchase, the insider now directly owns 10,921,009 shares of the company’s stock, valued at $772,115,336.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO G Doug Iiekking sold 6,570 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $126.25, for a total value of $829,462.50. Following the completion of the transaction, the chief financial officer now owns 2,200 shares of the company’s stock, valued at approximately $277,750. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 19,117 shares of company stock valued at $1,349,965 and sold 952,919 shares valued at $122,805,265. 53.20% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in USNA. Russell Investments Group Ltd. grew its stake in shares of USANA Health Sciences by 49.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 189,942 shares of the company’s stock worth $22,980,000 after acquiring an additional 63,247 shares during the period. Robeco Institutional Asset Management B.V. grew its stake in shares of USANA Health Sciences by 53.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 241,011 shares of the company’s stock worth $29,053,000 after acquiring an additional 83,672 shares during the period. Seven Eight Capital LP bought a new position in shares of USANA Health Sciences during the 3rd quarter worth $1,724,000. Strategic Advisors LLC bought a new position in shares of USANA Health Sciences during the 3rd quarter worth $346,000. Finally, NEXT Financial Group Inc bought a new position in shares of USANA Health Sciences during the 3rd quarter worth $121,000. Hedge funds and other institutional investors own 51.48% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Story: Bull Market
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.